Companies /Healthcare
Cencora Inc
NYSE: COR Medical Distribution
$345.69
▼ $4.87 (−1.39%) today
Markets open · 10:57am ET

Cencora (COR) Earnings History & Trends

EPS and revenue vs. Street estimates · SEC filings
COR vs Market · 30-day return after each reportCORS&P 500
−5%0%+5%+10%−6.8%+6.9%Q2 25+5.0%+2.5%Q3 25−4.6%+0.9%Q4 25+9.7%−1.2%Q1 26+8.4%+0.7%Q2 26+4.3%+0.1%Q3 26
−5%0%+5%+10%Q2 25Q4 25Q2 26
COR EPS Trend · estimate vs actualEstimateActual
$0$2$4$4.10$4.42Q2 25$3.84$4.00Q3 25$3.79$3.84Q4 25$4.04$4.08Q1 26$4.73$4.75Q2 26$4.57$4.66Q4 26
$0$2$4Q2 25Q4 25Q2 26
COR Revenue Trend · estimate vs actualEstimateActual
$0$30.0B$60.0B$90.0B$75.8B$75.5BQ2 25$80.1B$80.7BQ3 25$83.4B$83.7BQ4 25$86.2B$85.9BQ1 26$81.0B$78.4BQ2 26$87.9B$88.4BQ4 26
$0$30.0B$60.0B$90.0BQ2 25Q4 25Q2 26

How Often Does Cencora Beat Earnings Estimates?

Cencora beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 6 quarters in a row.

COR quarterly earnings per share and revenue versus Street estimates
Quarter EPS · est. Surprise Revenue · est. Surprise
Q4 2026 Adjusted EPS excludes Q4 items including $177.4 million of acquisition and divestiture-related deal and integration expenses, $116.0 million acquisition-related intangibles amortization, and tax discrete items. The tax items include an $87.1 million tax benefit related to the pending MWI Animal Health divestiture and a $146.8 million unfavorable Swiss deferred tax asset valuation adjustment. GAAP diluted EPS was $2.71. $4.66 est. $4.57 +1.88% $88.4B est. $87.9B +0.50%
Q3 2026 $4.48 — $84.8B —
Q2 2026 $4.75 est. $4.73 +0.48% $78.4B est. $81.0B −3.31%
Q1 2026 $4.08 est. $4.04 +0.99% $85.9B est. $86.2B −0.28%
Q4 2025 $3.84 est. $3.79 +1.44% $83.7B est. $83.4B +0.40%
Q3 2025 $4.00 est. $3.84 +4.23% $80.7B est. $80.1B +0.68%
Q2 2025 $4.42 est. $4.10 +7.92% $75.5B est. $75.8B −0.46%

Figures from SEC filings and company reports. Not investment advice.